Fibromyalgia research presents unique challenges for clinical trial sponsors and CROs. From accurately capturing subjective pain outcomes to ensuring long-term patient adherence, trials in this therapeutic area demand both scale and operational precision. DelRicht Research has built a reputation for meeting these challenges head-on, delivering consistent results that advance therapeutic innovation.

Proven Experience and Impact

Over the past five years, DelRicht Research has conducted more than five fibromyalgia trials, enrolling 400+ participants across diverse patient populations. With 13 sites recognized as Top Enrollers in fibromyalgia studies over the last four years, our performance demonstrates both reach and reliability.

Most recently, DelRicht was proud to support the FDA approval of Tonmya (Tonix Therapeutics), a milestone therapy in the fibromyalgia space. This achievement underscores the importance of consistent trial execution and high-quality data capture across our network. By pairing operational excellence with strong site engagement, DelRicht plays a critical role in helping sponsors bring new options to patients faster. Together with our earlier contributions to the approval of Stanza (Swing Therapeutics), these successes highlight the tangible impact of our work in advancing fibromyalgia care.

Nationwide Network and Infrastructure

DelRicht’s fibromyalgia research network spans 17+ dedicated sites nationwide, backed by 17 general medicine investigators and more than 300 years of collective principal investigator experience. This physician-led model is embedded within active community-based clinics, enabling immediate access to real-world patient populations while maintaining seamless operational integration.

Each site is equipped with full-service infrastructure, including access to local laboratories, secure IP storage, and specialty care providers. This standardization across the network ensures consistency in execution and inspection readiness at every location.

Operational Expertise for Complex Protocols

Fibromyalgia protocols often require heightened sensitivity around subjective endpoints such as pain, sleep disturbance, and fatigue. DelRicht’s embedded, high-volume sites are structured to address these nuances directly. Our teams are trained to:

– Ensure accurate pain reporting through validated workflows
– Reduce placebo response by building trust and continuity with patients
– Reinforce diary and dosing compliance through reminders, education, and dedicated staff follow-up

These measures safeguard endpoint integrity and strengthen overall trial reliability.

Patient-Centered Retention and Compliance

Retention in fibromyalgia research can be challenging, given the chronic and fluctuating nature of the condition. DelRicht mitigates this risk through integrated patient support systems, including real-time consent assistance, condition-specific education, and proactive follow-up. By prioritizing the patient experience, we sustain high retention and compliance rates that reduce data variability and improve trial outcomes.

A Trusted Partner Across Therapeutic Areas

While fibromyalgia is a leading area of expertise, DelRicht Research brings broad therapeutic experience across general medicine, including migraine, osteoarthritis, gout, obesity, diabetes, asthma, and vaccines. This cross-indication knowledge further strengthens our ability to navigate complex trial designs and adapt operational models to meet sponsor needs.

Moving Medicine Forward

From FDA-supported approvals to top-enrolling site performance, DelRicht Research has demonstrated its ability to deliver in one of the most challenging therapeutic spaces. For sponsors and CROs seeking a proven partner in fibromyalgia research, our investigator-led network offers the experience, infrastructure, and patient access needed to ensure trial success.

Learn more about our fibromyalgia performance and capabilities by downloading the performance summary one sheet. Partner with us to advance your next fibromyalgia trial.